



DHG PHARMACEUTICAL JOINT STOCK COMPANY

(Incorporated in the Socialist Republic of Vietnam)

REVIEWED INTERIM FINANCIAL STATEMENTS

For the 6-month period ended 30 June 2026

DHG PHARMACEUTICAL JOINT STOCK COMPANY

288 Bis Nguyen Van Cu Street, Cai Khe Ward

Can Tho City, Vietnam

TABLE OF CONTENTS

<u>CONTENTS</u>	<u>PAGE(S)</u>
STATEMENT OF THE MANAGEMENT	1 - 2
REPORT ON REVIEW OF INTERIM FINANCIAL STATEMENTS	3
INTERIM STATEMENT OF FINANCIAL POSITION	4 - 6
INTERIM INCOME STATEMENT	7
INTERIM CASH FLOW STATEMENT	8 - 9
NOTES TO THE INTERIM FINANCIAL STATEMENTS	10 - 43

DHG PHARMACEUTICAL JOINT STOCK COMPANY

288 Bis Nguyen Van Cu Street, Cai Khe Ward

Can Tho City, Vietnam

STATEMENT OF THE MANAGEMENT

The Management of DHG Pharmaceutical Joint Stock Company (the "Company") presents this report together with the Company's interim financial statements for the 6-month period ended 30 June 2026.

THE BOARD OF DIRECTORS, AUDIT COMMITTEE AND MANAGEMENT

The members of the Board of Directors, Audit Committee and Management of the Company who held office during the period and to the date of this report are as follows:

Board of Directors

Ms. Dang Thi Thu Ha	Chairwoman
Mr. Jun Kuroda	Member
Mr. Toshiyuki Ishii	Member (to 21 April 2026)
Mr. Maki Kamijo	Member
Ms. Le Thi Thanh Hien	Member
Mr. Do Le Hung	Independent member
Mr. Truong Anh Hung	Independent member
Ms. Sawa Sawada	Member (from 21 April 2026)

Audit Committee

Mr. Do Le Hung	Chairman
Mr. Maki Kamijo	Member
Ms. Le Thi Thanh Hien	Member

Management

Mr. Toshifumi Kojima	Acting General Director
Mr. Osamu Fujimori	Deputy General Director
Ms. Nguyen Ngoc Diep	Deputy General Director
Mr. Tomoyuki Kawata	Deputy General Director
Mr. Nguyen Ngoc Chuong	Production Director
Mr. Ta Thanh Hung	Information Technology Director
Mr. Hitoshi Okamoto	Quality Director (from 1 July 2026)

Legal representative

Legal representative of the Company during the period and at the date of these interim financial statements is Mr. Toshifumi Kojima.

THE MANAGEMENT'S STATEMENT OF RESPONSIBILITY

The Management of the Company is responsible for preparing the interim financial statements which give a true and fair view of the financial position of the Company as at 30 June 2026 and its financial performance and cash flows for the 6-month period then ended in accordance with Vietnamese Accounting Standards, accounting regime for enterprises and legal regulations relating to interim financial reporting. In preparing these interim financial statements, the Management is required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable accounting principles have been followed, subject to any material departures disclosed and explained in the interim financial statements;
- prepare the interim financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business; and
- design and implement an effective internal control system for the purpose of properly preparing and presenting the interim financial statements so as to minimize errors and frauds.

DHG PHARMACEUTICAL JOINT STOCK COMPANY

288 Bis Nguyen Van Cu Street, Cai Khe Ward

Can Tho City, Vietnam

STATEMENT OF THE MANAGEMENT (Continued)

The Management is responsible for ensuring that proper accounting records are kept, which disclose, with reasonable accuracy at any time, the financial position of the Company and that the interim financial statements comply with Vietnamese Accounting Standards, accounting regime for enterprises and legal regulations relating to interim financial reporting. The Management is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of frauds and other irregularities.

The Management confirms that the Company has complied with the above requirements in preparing these interim financial statements.

For and on behalf of the Management,




Toshifumi Kojima
Acting General Director
Legal representative
13 August 2026

No.: 0142 /VN1A-HC-BC

REPORT ON REVIEW OF INTERIM FINANCIAL STATEMENTS

**To: The Shareholders
The Board of Directors, Audit Committee and Management
DHG Pharmaceutical Joint Stock Company**

We have reviewed the accompanying interim financial statements of DHG Pharmaceutical Joint Stock Company (the "Company"), prepared on 13 August 2026 as set out from page 4 to page 43, which comprise the interim statement of financial position as at 30 June 2026, the interim income statement and interim cash flow statement for the 6-month period then ended and a summary of significant accounting policies and other explanatory information.

The Management's Responsibility for the Interim Financial Statements

The Management is responsible for the preparation and fair presentation of these interim financial statements in accordance with Vietnamese Accounting Standards, accounting regime for enterprises and legal regulations relating to interim financial reporting, and for such internal control as the Management determines is necessary to enable the preparation of interim financial statements that are free from material misstatement, whether due to fraud or error.


Auditors' Responsibility

Our responsibility is to express a conclusion on the accompanying interim financial statements based on our review. We conducted our review in accordance with Vietnamese Standard on Review Engagements (VSRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity".

A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial statements do not present fairly, in all material respects, the financial position of the Company as at 30 June 2026, and of its financial performance and its cash flows for the 6-month period then ended in accordance with Vietnamese Accounting Standards, accounting regime for enterprises and legal regulations relating to interim financial reporting.



Nguyễn Thị Thu Sang
Audit Partner

Audit Practising Registration Certificate

No. 1144-2023-001-1

**BRANCH OF DELOITTE VIETNAM AUDIT
COMPANY LIMITED**

13 August 2026

Ho Chi Minh City, Vietnam

INTERIM STATEMENT OF FINANCIAL POSITION
As at 30 June 2026

Unit: VND

ASSETS	Codes	Notes	Closing balance	Opening balance
A. CURRENT ASSETS	100		3,744,552,782,262	3,888,768,378,369
I. Cash and cash equivalents	110	6	181,908,206,384	129,895,664,996
1. Cash	111		181,908,206,384	129,895,664,996
II. Short-term financial investments	120	7	1,582,918,136,980	2,085,046,506,858
1. Short-term held-to-maturity investments	123	7	1,583,042,529,184	2,085,182,539,062
2. Provision for short-term held-to-maturity investments	124	7	(124,392,204)	(136,032,204)
III. Short-term receivables	130		684,852,182,022	623,204,653,868
1. Short-term trade receivables	131	8	650,937,022,307	615,182,622,035
2. Short-term advances to suppliers	132	9	47,649,994,153	20,166,835,882
3. Other short-term receivables	135	10	16,511,440,507	17,971,609,804
4. Provision for short-term doubtful debts	136	11	(30,246,274,945)	(30,116,413,853)
IV. Inventories	140	12	1,236,195,662,224	1,024,618,562,192
1. Inventories	141		1,248,549,258,280	1,031,188,044,691
2. Provision for devaluation of inventories	142		(12,353,596,056)	(6,569,482,499)
V. Other short-term assets	160		58,678,594,652	26,002,990,455
1. Short-term deferred expenses	161	13	30,158,408,441	12,987,475,608
2. Value added tax deductibles	162		13,000,527,601	12,307,871,131
3. Taxes and other receivables from the State budget	163	21	15,519,658,610	707,643,716

The accompanying notes are an integral part of these interim financial statements



INTERIM STATEMENT OF FINANCIAL POSITION (Continued)
As at 30 June 2026

Unit: VND

ASSETS	Codes	Notes	Closing balance	Opening balance
B. NON-CURRENT ASSETS	200		1,260,934,747,962	1,285,113,250,628
I. Long-term receivables	210		5,866,574,169	5,608,830,169
1. Other long-term receivables	215	10	5,866,574,169	5,608,830,169
II. Fixed assets	220		1,113,842,059,711	1,142,828,934,460
1. Tangible fixed assets	221	14	940,817,448,375	968,409,065,544
- Cost	222		2,230,382,744,472	2,199,969,625,684
- Accumulated depreciation	223		(1,289,565,296,097)	(1,231,560,560,140)
2. Intangible assets	227	15	173,024,611,336	174,419,868,916
- Cost	228		234,288,626,721	234,288,626,721
- Accumulated amortization	229		(61,264,015,385)	(59,868,757,805)
III. Investment property	240	16	29,460,048,585	29,864,239,743
- Cost	241		44,826,611,143	44,826,611,143
- Accumulated depreciation	242		(15,366,562,558)	(14,962,371,400)
IV. Long-term assets in progress	250	17	50,276,567,288	44,157,626,600
1. Long-term construction in progress	252		50,276,567,288	44,157,626,600
V. Long-term financial investments	260		4,350,000,000	4,630,000,000
1. Equity investments in other entities	263	7	24,108,379,057	24,108,379,057
2. Provision for impairment of long-term investments in other entities	264	7	(19,758,379,057)	(19,478,379,057)
VI. Other long-term assets	270		57,139,498,209	58,023,619,656
1. Long-term deferred expenses	271	13	30,677,415,760	32,094,203,855
2. Deferred tax assets	272	18	26,462,082,449	25,929,415,801
TOTAL ASSETS (280=100+200)	280		5,005,487,530,224	5,173,881,628,997

The accompanying notes are an integral part of these interim financial statements



Unit: VND

5,005,487,530,22

Toshifumi Kojima
Acting General Director
Legal representative
Approved on 13 August 2026

6

INTERIM INCOME STATEMENT
For the 6-month period ended 30 June 2026

Unit: VND

ITEMS	Codes	Notes	Current period	Prior period
1. Gross revenue from goods sold and services rendered	01	31	2,880,432,772,781	2,766,028,789,278
2. Deductions	02	31	319,182,118,268	387,246,998,277
3. Net revenue from goods sold and services rendered (10=01-02)	10	31	2,561,250,654,513	2,378,781,791,001
4. Cost of sales	11	32	1,253,223,276,543	1,226,169,303,615
5. Gross profit from goods sold and services rendered (20=10-11)	20		1,308,027,377,970	1,152,612,487,386
6. Financial income	22	34	59,722,454,402	68,161,733,319
7. Financial expenses	23	35	22,814,787,598	42,700,967,232
- In which: Borrowing costs	24		-	12,697,085,263
8. Selling expenses	25	36	453,448,561,324	456,650,534,767
9. General and administration expenses	26	36	179,868,709,308	156,714,385,965
10. Operating profit (30=20+(22-23)-(25+26))	30		711,617,774,142	564,708,332,741
11. Other income	31	37	1,508,204,308	9,426,060,049
12. Other expenses	32	38	7,610,662,593	8,594,625,307
13. (Loss)/profit from other activities (40=31-32)	40		(6,102,458,285)	831,434,742
14. Accounting profit before tax (50=30+40)	50		705,515,315,857	565,539,767,483
15. Current corporate income tax expense	51	39	91,703,142,028	62,738,004,730
16. Deferred corporate tax income	52	39	(532,666,648)	(332,951,226)
17. Net profit after corporate income tax (60=50-51-52)	60		614,344,840,477	503,134,713,979
18. Basic earnings per share	70	40	4,558	3,733


Tran Ngoc Hien
Preparer


Ho Bui Huan
Chief Accountant


Toshifumi Kojima
Acting General Director
Legal representative
Approved on 13 August 2026



1-002-C
HÀNH
TNHH
OÁN
TTE
AM
CHÍ M

INTERIM CASH FLOW STATEMENT
(Indirect method)
For the 6-month period ended 30 June 2026

Unit: VND

ITEMS	Codes	Current period	Prior period
I. CASH FLOWS FROM OPERATING ACTIVITIES			
1. Profit before tax	01	705,515,315,857	565,539,767,483
2. Adjustments for:			
Depreciation and amortization of fixed assets and investment properties	02	59,585,011,364	59,406,377,673
Provisions	03	9,640,785,807	3,150,286,085
Foreign exchange gain arising from translating foreign currency items	04	(56,931,020)	(96,237,333)
Gain from investing activities	05	(50,068,646,930)	(63,713,883,110)
Borrowing costs	06	-	12,697,085,263
3. Operating profit before movements in working capital	08	724,615,535,078	576,983,396,061
Changes in receivables	09	(54,611,773,528)	111,463,869,081
Changes in inventories	10	(217,361,213,589)	27,764,187,780
Changes in payables	11	(137,272,850,478)	53,134,863,943
Changes in deferred expenses	12	(15,754,144,738)	18,286,865,528
Borrowing costs paid	14	-	(12,577,047,203)
Corporate income tax paid	15	(66,278,007,602)	(36,341,225,553)
Other cash outflows	17	(13,145,870,431)	(18,854,499,986)
Net cash generated by operating activities	20	220,191,674,712	719,860,409,651
II. CASH FLOWS FROM INVESTING ACTIVITIES			
1. Acquisition and construction of fixed assets and other long-term assets	21	(66,489,303,928)	(20,577,566,076)
2. (Payments for)/proceeds from sale, disposal of fixed assets and other long-term assets	22	(89,300,000)	156,174,545
3. Cash outflow for lending and time deposits	23	(1,125,000,000,000)	(1,944,000,000,000)
4. Cash recovered from lending and time deposits	24	1,599,011,640,000	2,214,000,000,000
5. Interest earned, dividends and profits received	27	78,286,316,808	77,708,453,776
Net cash generated by investing activities	30	485,719,352,880	327,287,062,245
III. CASH FLOWS FROM FINANCING ACTIVITIES			
1. Proceeds from borrowings	33	-	1,352,569,329,050
2. Repayment of borrowings	34	-	(1,074,913,916,414)
3. Dividends and profits paid	36	(653,730,355,000)	(1,307,460,710,000)
Net cash used in financing activities	40	(653,730,355,000)	(1,029,805,297,364)
Net increase in cash (50=20+30+40)	50	52,180,672,592	17,342,174,532
Cash and cash equivalents at the beginning of the period	60	129,895,664,996	62,857,547,612
Effects of changes in foreign exchange rates	61	(168,131,204)	70,663,682
Cash and cash equivalents at the end of the period (70=50+60+61)	70	181,908,206,384	80,270,385,826

The accompanying notes are an integral part of these interim financial statements

INTERIM CASH FLOW STATEMENT (Continued)

(Indirect method)

For the 6-month period ended 30 June 2026

Significant non-cash transactions for the 6-month period ended 30 June 2026 are presented in Note 43.

		
Tran Ngoc Hien Preparer	Ho Bui Huan Chief Accountant	 Toshifumi Kojima Acting General Director Legal representative Approved on 13 August 2026

NOTES TO THE INTERIM FINANCIAL STATEMENTS

These notes are an integral part of and should be read in conjunction with the interim financial statements

1. GENERAL INFORMATION**Structure of ownership**

DHG Pharmaceutical Joint Stock Company (the "Company"), formerly known as Hau Giang Pharmaceutical United Enterprise of Can Tho City, was equitized from a state-owned enterprise into a joint stock company according to Enterprise Registration Certificate No. 5703000111 issued by the Department of Planning and Investment Can Tho City on 15 September 2004 and the latest amended Enterprise Registration Certificate (32nd amendment) was issued by the Department of Finance of Can Tho City on 5 January 2026.

The Company's shares were listed in Ho Chi Minh Stock Exchange with DHG code in accordance with Decision No. 93/UBCK-GPNY dated 1 December 2006 issued by the State Securities Commission of Vietnam.

As at 30 June 2026, the largest shareholders of the Company are Taisho Pharmaceutical Co., Ltd. which owns 51.01% and the State Capital Investment Corporation ("SCIC") which owns 43.31% of share capital of the Company. SCIC is controlled by the Ministry of Finance in accordance with Official Letter No. 1661/VPCP-DMDN dated 28 February 2025.

The Company's head office is located at 288 Bis Nguyen Van Cu Street, Cai Khe Ward, Can Tho City, Vietnam. In addition, the Company operates thirty-four (34) distribution branches, two (2) representative offices, and two (2) central warehouses, and one (1) medical herb branch located across various provinces and cities in Vietnam.

As at 30 June 2026, the Company has following active manufacturing plants:

1. DHG Pharmaceutical Manufacturing Plant, located at the Company's head office address.
2. DHG Pharmaceutical Manufacturing Plant (including the expansion project), located at Lot B2 - B3, Tan Phu Thanh Industrial Park – Phase 1, Thanh Xuan Commune, Can Tho City (formerly part of Hau Giang Province).
3. DHG Packaging-Printing Plant, located at Lot B2 - B3, Tan Phu Thanh Industrial Park – Phase 1, Thanh Xuan Commune, Can Tho City (formerly part of Hau Giang Province).

The number of employees of the Company as at 30 June 2026 was 2,805 (as at 31 December 2025: 2,819).

Operating industry and principal activities

The Company's operating industry and principal activities are to manufacture and trade pharmaceuticals, health-protecting supplements and cosmeceuticals.

Normal production and business cycle

The Company's normal production and business cycle is carried out for a time period of 12 months or less.

Disclosure of information comparability in the interim financial statements

Comparative figures on the interim statement of financial position are the figures of the audited financial statements for the year ended 31 December 2025 and comparative figures on the interim income statement and interim cash flow statement are the figures of the reviewed interim financial statements for the 6-month period ended 30 June 2025. Certain comparative figures have been reclassified to conform to the presentation adopted in the current period which are disclosed in Note 3.

2. ACCOUNTING CONVENTION AND FINANCIAL YEAR/ACCOUNTING PERIOD

Accounting convention

The interim financial statements, expressed in Vietnam Dong (VND), are prepared under the historical cost convention and in accordance with Vietnamese Accounting Standards, accounting regime for enterprises and legal regulations relating to interim financial reporting.

The interim financial statements are not intended to present the financial position, results of operations and cash flows in accordance with accounting principles and practices generally accepted in countries and jurisdictions other than Vietnam.

Financial year/accounting period

The Company's financial year begins on 1 January and ends on 31 December. The interim financial statements are prepared for the 6-month period ended 30 June each period.

3. ADOPTION OF NEW ACCOUNTING GUIDANCE

On 27 October 2025, the Minister of Finance issued Circular No. 99/2025/TT-BTC ("Circular 99"), providing guidance on the accounting regime for enterprises. Circular 99 is effective for financial years beginning on or after 1 January 2026. Circular 99 replaces the accounting regime for enterprises previously issued under Circular No. 200/2014/TT-BTC issued on 22 December 2014 by the Ministry of Finance. The Management has applied Circular 99 in the preparation and presentation of the interim financial statements for the 6-month period ended 30 June 2026.

As a result of the changes introduced by Circular 99, certain line items in the interim financial statements have been newly added, amended, combined or split, and some line-item codes have also been changed. Accordingly, the comparative information presented in these interim financial statements has been reclassified to conform to the presentation requirements under Circular 99.

The Management adopted the accounting policy changes required by Circular 99 that are applicable to the Company on a prospective basis, as Circular 99 does not require retrospective application of these changes. The Management also represented the comparative figures for the prior period for certain line items to conform with the presentation requirements under Circular 99, as disclosed as below:

Extract from the Interim Statement of Financial Position

Unit: VND

Code	ASSETS		31 December 2025 (as presented under Circular 200)	Reclassified amount	1 January 2026 (reclassified under Circular 99)
120	Short-term financial investments		2,024,000,000,000	61,046,506,858	2,085,046,506,858
123	Short-term held-to-maturity investments	[1]	2,024,000,000,000	61,182,539,062	2,085,182,539,062
124	Provision for short-term held-to-maturity investments	[2]	-	(136,032,204)	(136,032,204)
130	Short-term receivables		684,251,160,726	(61,046,506,858)	623,204,653,868
	Short-term loan receivables	[3]	136,032,204	(136,032,204)	-
135	Other short-term receivables	[4]	79,018,116,662	(61,046,506,858)	17,971,609,804
136	Provision for short-term doubtful debts	[2]	(30,252,446,057)	136,032,204	(30,116,413,853)

- [1] Reclassification adjustment arising from the adjustments described in [3] and [4].
- [2] To reclassify the provision related to short-term loans from "Provision for short-term doubtful debts" to "Provision for short-term held-to-maturity investments".
- [3] To reclassify "Short-term loan receivables" to "Short-term held-to-maturity investments".
- [4] To reclassify accrued interest receivable on term deposits from "Other short-term receivables" to "Short-term held-to-maturity investments".

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies, which have been adopted by the Company in the preparation of these interim financial statements, are as follows:

Estimates

The preparation of interim financial statements in conformity with Vietnamese Accounting Standards, accounting regime for enterprises and legal regulations relating to interim financial reporting requires the Management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the interim statement of financial position date and the reported amounts of revenues and expenses during the period. Although these accounting estimates are based on the Management's best knowledge, actual results may differ from those estimates.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, demand deposits, cash in transit and short-term, highly liquid investments (not exceeding 3 months) that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value and are not restricted in use.

Financial investments

Held-to-maturity investments

Held-to-maturity investments are investments that the Company has the intention and ability to hold until maturity.

Held-to-maturity investments include term deposits to earn periodic interest (except for term deposits presented in Note "Cash and cash equivalents") and loans held to maturity for the purpose of earning periodic interest.

Held-to-maturity investments are initially recognized at cost. Subsequent to initial recognition, interest received at maturity or periodically is recognized as an increase in held-to-maturity investments and finance income in the relevant interest periods.

Held-to-maturity investments are measured at cost less provision for held-to-maturity investments.

Provision for held-to-maturity investments is recognised when there is any indication or objective evidence that part or all of the Company's held-to-maturity investments may not be recoverable.



Equity investments in other entities

Equity investments in other entities represent investments in equity instruments over which the Company does not have control, joint control or significant influence over the investee.

Equity investments in other entities are carried at cost less provision for impairment (if any).

A provision for impairment of investments in other entities is recognised when the investee incurs losses or when such investments are impaired, indicating that the Company may not be able to recover its investment.

Receivables

Receivables represent the amounts recoverable from customers or other debtors and are stated at book value less provision for doubtful debts.

Provision for doubtful debts is made for receivables that are overdue for six months or more, or when the debtor is in dissolution, in bankruptcy, or is experiencing similar difficulties and so may be unable to repay the debt.

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost of inventories comprises cost of purchases and other directly attributable expenses. In the case of manufactured products, cost comprises direct materials and where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition.

The Company determines the cost of inventories issued on a per-transaction basis for accounting inventory.

Cost is calculated using the weighted average method. Net realizable value represents the estimated selling price less all estimated costs to completion and costs to be incurred in marketing, selling and distribution.

The evaluation of necessary provision for inventory obsolescence follows current prevailing accounting regulations which allow provisions to be made for obsolete, damaged, or sub-standard inventories and for those which have costs higher than net realizable values as at the interim statement of financial position date.

Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost, accumulated depreciation and net book value.

The costs of purchased tangible fixed assets comprise their purchase prices and any directly attributable costs of bringing the assets to the location and condition necessary for it to be capable of operating in the manner intended by management.

The costs of self-constructed or manufactured assets are the actual construction or manufacturing cost plus installation and test running costs, and any directly attributable costs of bringing the assets to their working condition and location required for them to be capable of operating as intended.

Tangible fixed assets are depreciated using the straight-line method over their estimated useful lives, as follows:

	<u>Years</u>
Buildings and structures	3 - 50
Machinery and equipment	5 - 20
Office equipment	3 - 15
Motor vehicles	3 - 15



Operating leases

The Company as lessee

Leases where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Rentals payable under operating leases are charged to the interim income statement on a straight-line basis over the term of the relevant lease. Benefits received and receivable as an incentive to enter into an operating lease are also spread on a straight-line basis over the lease term.

Intangible fixed assets and amortization

The costs of intangible assets comprise all expenditures incurred by the Company to acquire such assets up to the point at which the asset is in a condition capable of operating in the manner intended by management.

Intangible assets comprise land use rights and computer software, and are stated at cost less accumulated amortization.

Definite land use rights are amortized using the straight-line method over the terms indicated in the land use right certificate. Indefinite land use rights are carried at cost and not amortized under prevailing regulations.

Computer software is amortized using the straight-line method from 2 to 8 years.

Investment properties

Investment properties are buildings, or part of buildings or infrastructure held by the Company to earn rentals or for capital appreciation. Investment properties held to earn rentals are stated at cost less accumulated depreciation while investment properties held for capital appreciation are stated at cost less impairment loss. The costs of purchased investment properties comprise their purchase prices and any directly attributable expenditures, such as professional fees for legal services, property transfer taxes and other related transaction costs. The costs of self-constructed investment properties are the finally accounted construction or directly attributable costs of the properties.

Investment properties held to earn rentals are depreciated using the straight-line method over their estimated useful lives, as follows:

	Years
Land use rights	50
Building and structures	10 -15

Construction in progress

Properties in the course of construction for production, rental or administrative purposes, or for other purposes, are carried at cost. Cost includes costs that are necessary to form the assets in accordance with the Company's accounting policy. Depreciation of these assets, on the same basis as other assets, commences when the assets are ready for their intended use.

Deferred expenses

Deferred expenses are expenses which have already been paid but relate to results of operations of multiple accounting periods. Deferred expenses comprise leasehold improvement expenses, land rentals, costs of small tools, supplies and spare parts issued for consumption and other deferred expenses.

Land rentals represent the prepaid land rentals. The prepaid land rentals are allocated to the interim income statement using the straight-line method over the lease term.

Other types of deferred expenses comprise costs of small tools, supplies and spare parts issued for consumption which are expected to provide future economic benefits to the Company. These expenditures are allocated to the interim income statement using the method in accordance with the current prevailing accounting regulations.

Trade payables

Trade payables represent liabilities arising from the purchase of goods, services or assets from suppliers in the ordinary course of the Company's business. Trade payables are stated at historical cost.

Dividends and profit payable

Dividends and profit payable represent dividends payable to shareholders. Dividends payable are recognised when the Company no longer has the right to avoid the obligation to make such dividends distributions to shareholders in accordance with applicable laws and regulations.

Accrued expenses

Accrued expenses comprise amounts payable for goods and services received by the Company but not yet paid due to the absence of sufficient supporting documentation, and are recognised in the interim income statement in the accounting period.

Deferred revenue

Deferred revenue represents the value of goods and services to be provided to customers in connection with discounts granted under the Company's customer loyalty program relating to multiple accounting periods. The Company recognises deferred revenue in proportion to its obligations that the Company will have to fulfill in the future. When the revenue recognition conditions are satisfied, deferred revenue will be recognised in the interim income statement for the period corresponding to the portion that meets the revenue recognition conditions.

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the management's best estimate of the consideration required to settle the present obligation at the end of accounting period.

Severance allowance payable

The severance allowance for employees is recognised at the end of each reporting period for all employees having worked at the Company for full 12 months and above. Working time serving as the basis for calculating severance allowance shall be the total actual working time subtracting the time when the employees have made unemployment insurance contributions as prescribed by law, and the working time when severance allowance has been paid to the employees. The allowance made for each period of service equals to a half of an average monthly salary under the Vietnamese Labour Code, Social Insurance Code and relevant guiding documents. The average monthly salary used for calculation of severance allowance shall be adjusted to be the average of the 6 consecutive months nearest to the date of the interim financial statements at the end of each reporting period. The increase or decrease in the accrued amount shall be recorded in the interim income statement.

Provision for dismantling and restoration costs

The Company recognizes a provision for dismantling and restoration costs associated with the obligation to return the leased premises or land to their original condition. The provision is determined based on the total estimated costs required to dismantle and restore premises at the time they are returned in the future. The provision is recognized on a straight-line basis over the period from the date the obligation arises (or from 1 January 2015 for obligations that arose prior to the effective date of Circular No. 200/2014/TT-BTC issued by the Ministry of Finance), until the date the premises or land are returned or the expected dismantling date.

Equity

Ordinary shares

Ordinary shares with voting rights are recognised at par value. Shares issued to increase charter capital or shareholders' contributed capital are recognised based on the actual proceeds received corresponding to the par value of successfully issued shares.

Share premium

Share premium represents the difference between the par value and the issuance price of ordinary shares, net of costs directly attributable to the share issuance.

Costs directly attributable to the share issuance are allocated between successfully issued shares and unsuccessfully issued shares as follows:

- The portion allocated to successfully issued shares is offset against share premium.
- The portion related to unsuccessfully issued shares is recognised as financial expenses for the period.

Profit distribution

The Company's net profit after tax is available for appropriation to shareholders as dividends and funds upon approval by shareholders at the Company's Annual General Meeting.

Dividends are declared and paid from retained earnings based on the approval of shareholders at the Company's Annual General Meeting.

Bonus and welfare fund

Bonus and welfare fund is deducted from the profit after corporate income tax of the Company to be used for rewarding and encouraging physical benefits, serving the needs of the public, improving and enhancing mental, physical life of employees and funding the operating activities of the Board of Directors as approved by the resolution of the Company's Annual General Meeting of Shareholders. The appropriation and use of the bonus and welfare fund must comply with current prevailing accounting and financial regulations.

Investment and development fund

Investment and development fund is deducted from profits after corporate income tax of the Company to be used to invest in expanding the scale of production, business or in-depth investment of the enterprise. The appropriation and use of the investment and development fund shall be carried out in accordance with the Resolution of the Annual General Meeting of Shareholders and the prevailing regulations.



Revenue and other income recognition

Sales of goods

Revenue from the sale of goods is recognized when all five (5) following conditions are satisfied:

- (a) the Company has transferred to the buyer the significant risks and rewards of ownership of the goods;
- (b) the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- (c) the amount of revenue can be measured reliably;
- (d) it is probable that the economic benefits associated with the transaction will flow to the Company; and
- (e) the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Sales of rendering services

Revenue of a transaction involving the rendering of services is recognized when the outcome of such transactions can be measured reliably. Where a transaction involving the rendering of services is attributable to several periods, revenue is recognized in each period by reference to the percentage of completion of the transaction at the statement of financial position date of that period. The outcome of a transaction can be measured reliably when all four (4) following conditions are satisfied:

- (a) the amount of revenue can be measured reliably;
- (b) it is probable that the economic benefits associated with the transaction will flow to the Company;
- (c) the percentage of completion of the transaction at the interim statement of financial position date can be measured reliably; and
- (d) the costs incurred for the transaction and the costs to complete the transaction can be measured reliably.

Customer loyalty programs

Revenue is recognised at total consideration receivable or received, less fair value of goods and services to be provided for free of charge or discounts and rebates granted to customers. The fair value of goods or services to be provided free of charge, or the amount of discounts and rebates granted to customers, is recognised as deferred revenue. Where customers do not satisfy the conditions stated in the customer loyalty programs by the end of the program period and are therefore not entitled to the free goods or service, or discounts and rebates, the deferred revenue is recognised as revenue from the sale of goods and rendering of services.

Where the Company directly provides free goods or services, or grants discounts or rebates to customers:

When customers satisfy the conditions of the program, the deferred revenue corresponding to the fair value of the free goods or services provided, or the discounts or rebates granted to customers, is recognised as revenue from the sale of goods and rendering of services upon delivery of the free goods or services to customers or when the discounts or rebates are granted in accordance with the terms of the program.

Where a third party is obligated to provide free goods or services, or grant discounts or rebates to customers, and the Company acts as a principal:

When customers satisfy the conditions of the program, the deferred revenue amount is recognised as revenue from the sale of goods and rendering of services when the third party provides the goods or services or grants the discounts or rebates.

Where a third party is obligated to provide free goods or services, or grant discounts or rebates to customers, and the Company acts as an agent:

When customers satisfy the conditions of the program, revenue is recognised in an amount equal to the difference between the deferred revenue balance and the amount payable to the third party.

Interest income from deposits and loans:

Interest income from deposits and loans is recognized on an accrual basis and is determined based on the outstanding balances of deposits and loans and the applicable interest rates.

Dividend income and profit distributions:

Dividend income from investments is recognized when the Company's right to receive payment has been established.

Other income:

Other income comprises income arising from infrequent transactions and activities that are not generated from the Company's principal revenue-generating activities.

Sales deductions

Sales deductions include trade discounts, sales allowances and sales returns.

Sales deductions incurred in the same period of the related revenue from sales of products, goods and rendering of services are recorded as a deduction from the revenue of that period. In case that sales deductions for sales of products, goods or rendering of services sold in the period incurred after the end of the reporting period but before the issuance of the interim financial statements, the Company recorded as revenue deductions for the period.

Cost of sales and services rendered

Cost of sales and services rendered comprises the cost of products, merchandise sold and services rendered during the period and is recorded in line with the related revenue recognised during the period.

Selling expenses

Selling expenses are expenses incurred that are directly related to the sale of products, merchandise and the rendering of services by the Company and are recognised as expenses in the period on an accrual basis.

General and administrative expenses

General and administrative expenses are expenses incurred in connection with the general administrative activities of the Company, which are not directly attributable to sales or production activities, and are recognised as expenses in the period on an accrual basis.

Foreign currencies

Transactions arising in foreign currencies are translated at exchange rates ruling at the transaction date. The balances of monetary items denominated in foreign currencies as at the date of interim statement of financial position are retranslated at the the average bank transfer buying and selling exchange rates of commercial bank where the Company usually transacts on the same date, except for demand deposits denominated in foreign currencies, which are translated at the average bank transfer buying and selling exchange rates quoted by the commercial bank where the Company maintains such deposit accounts. Exchange differences arising from the translation of these accounts are recognised in the interim income statement.

1250
HI NH
NG T
EM 1
LO
ET
HỒ H

Borrowing costs

Borrowing costs comprise interest expense and other costs directly attributable to the Company's borrowings.

Borrowing costs are recognised in profit or loss in the period in which they are incurred, except for borrowing costs that are capitalised in accordance with Vietnamese Accounting Standard No. 16 "Borrowing Costs". Accordingly, borrowing costs directly attributable to the construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are capitalized as part of the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. Any income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization.

Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable includes current corporate income tax expenses in accordance with the Corporate Income Tax Law and the top-up tax expenses under the global minimum tax regulations. The tax currently payable is based on taxable profit for the period. Taxable profit differs from profit before tax as reported in the interim income statement because it excludes items of income or expense that are taxable or deductible in other years (including loss carried forward, if any) and it further excludes items that are never taxable or deductible. The top-up tax expenses under the global minimum tax regulations represent the additional corporate income tax that the Company is required to pay to the State Budget, determined in accordance with applicable global minimum tax legislation.

Deferred tax is recognised on temporary differences between carrying amounts of assets and liabilities in the interim financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are recognised for all taxable temporary differences. Deferred tax assets are recognised only to the extent that it is probable that the Company will have future taxable profit against which the deductible temporary differences can be utilised.

Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset realised. Deferred tax is charged or credited to profit or loss, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same tax authority and the Company intends to settle its current tax assets and liabilities on a net basis.

The determination of the tax currently payable is based on the current interpretation of tax regulations. However, these regulations are subject to periodic variation and their ultimate determination depends on the results of the tax authorities' examinations.

Other taxes are paid in accordance with the prevailing tax laws in Vietnam.

Segmental reporting

A segment is a distinct business segment of the Company that provides a single product or service or a group of related products and services (product segment), or provides products and services within a particular economic environment (geographical segment). Each segment is subject to risks and returns that are different from those of others. The basic reportable segment of the Company is product segment.

Segment reporting is prepared and presented in accordance with accounting policies applied to the preparation and presentation of the Company's interim financial statements in order to help users of interim financial statements to understand and evaluate the operations of the Company in a comprehensive way.

Related parties

Parties are considered to be related parties of the Company if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions, or when the Company and other party are under common control or under common significant influence. Related parties can be enterprise or individual, including their close family members.

5. KEY ASSUMPTIONS AND ESTIMATES

Key assumptions and estimates concerning the future, which give rise to estimation uncertainty at the reporting date and may result in a significant risk of material adjustments to the carrying amounts of assets and liabilities in the next financial year, are presented below.

Provision for dismantling and restoration costs

Under the lease agreements, the Company is obligated to repair, maintain and restore the leased premises to their original condition upon the expiration of the lease term and is responsible for all related costs. Details are presented in Note 26.

In estimating the provision, the Management has made assumptions regarding the condition of the asset at the end of the lease term and has estimated the restoration costs based on currently available information, including market prices, inflation rates, discount rates and the expected timing of settlement of the obligation. Due to the inherent uncertainty associated with these assumptions, the estimates may require revision in future years if there are significant changes in these factors. The Management will continue to review and update these assumptions as additional information becomes available to ensure that the provision appropriately reflects the Company's present obligation.

Provision for doubtful receivables

The Company recognises a provision for doubtful receivables for outstanding receivables that are considered to be at risk of loss as at the interim statement of financial position date. The provision is determined based on the aging of overdue balances and other information relevant to the recoverability of each receivable.

Receivables are assessed for making provision based on overdue aging.

For overdue receivables, the provision is determined according to the following rates:

- | | |
|--|----------------------------------|
| • Overdue from 6 months to less than 1 year: | 30% of the outstanding balance; |
| • Overdue from 1 year to less than 2 years: | 50% of the outstanding balance; |
| • Overdue from 2 years to less than 3 years: | 70% of the outstanding balance; |
| • Overdue for 3 years or more: | 100% of the outstanding balance. |

For receivables that are not yet due but where the debtor is unlikely to settle the outstanding amount due to liquidation, bankruptcy or similar financial difficulties, the provision is estimated based on the expected amount of loss that may be incurred.

As these assessments are based on information and assumptions available at the reporting date, actual results may differ from the original estimates as a result of changes in debtors' financial condition, repayment capability, or future economic and market conditions. The Management will continue to review and update these assumptions in subsequent reporting periods to ensure that the carrying amounts of receivables appropriately reflect their recoverability.



6. CASH AND CASH EQUIVALENTS

	<u>Closing balance</u>	<u>Opening balance</u>
	VND	VND
Cash on hand	6,567,858,500	6,954,261,500
Bank demand deposits	175,340,347,884	122,941,403,496
	181,908,206,384	129,895,664,996

Details of demand deposit by each bank are as follows:

	<u>Closing balance</u>	<u>Opening balance</u>
	VND	VND
Joint Stock Commercial Bank for Foreign Trade of Vietnam	169,732,797,443	46,602,490,437
Vietnam Joint Stock Commercial Bank for Industry and Trade	5,520,612,795	76,223,189,186
Others	86,937,646	115,723,873
	175,340,347,884	122,941,403,496

DHG PHARMACEUTICAL JOINT STOCK COMPANY
NOTES TO THE INTERIM FINANCIAL STATEMENTS (Continued)

FORM B 09a-DN

7. FINANCIAL INVESTMENTS

Held-to-maturity investments

Short-term held-to maturity investments represent term deposits with the original maturity terms from more than 3 months and remaining maturity terms of less than 12 months from the statement of financial position date. The held-to-maturity investments bear interest rates ranging from 5.2% to 8.0% per annum (prior period: from 4.6% to 5.7% per annum).

	Closing balance			Opening balance (Reclassified)		
	Cost	Recoverable amount	Provision	Cost	Recoverable amount	Provision
	VND	VND	VND	VND	VND	VND
- Term deposits	1,582,918,136,980	1,582,918,136,980	-	2,085,046,506,858	2,085,046,506,858	-
Vietnam Joint Stock Commercial Bank						
For Industry and Trade	897,667,616,437	897,667,616,437	-	1,175,950,082,192	1,175,950,082,192	-
Joint Stock Commercial Bank for Foreign Trade of Vietnam	482,173,698,627	482,173,698,627	-	-	-	-
Joint Stock Commercial Bank for Investment and Development of Vietnam	203,076,821,916	203,076,821,916	-	909,096,424,666	909,096,424,666	-
- Loans	124,392,204	-	(124,392,204)	136,032,204	-	(136,032,204)
	1,583,042,529,184	1,582,918,136,980	(124,392,204)	2,085,182,539,062	2,085,046,506,858	(136,032,204)

Equity investments in other entities

	Closing balance			Opening balance		
	Ownership and voting percentage	Cost	Recoverable amount/fair value	Ownership and voting percentage	Cost	Recoverable amount/fair value
	%	VND	VND	%	VND	VND
ATP Packaging Joint Stock Company [1]	6.67	20,000,000,000	2,600,000,000 (17,400,000,000)	6.67	20,000,000,000	2,600,000,000 (17,400,000,000)
Enlie Pharmaceutical Joint Stock Company [2]	2.9	4,108,379,057	1,750,000,000 (2,358,379,057)	2.9	4,108,379,057	2,030,000,000 (2,078,379,057)
		24,108,379,057	4,350,000,000 (19,758,379,057)		24,108,379,057	4,630,000,000 (19,478,379,057)

[1] The fair value of investment in ATP Packaging Joint Stock Company was determined by P/B method.

[2] The fair value of investment in Enlie Pharmaceutical JSC was determined based on the reference price in the stock market exchange.

8. SHORT-TERM TRADE RECEIVABLES

	Closing balance		Opening balance	
	Carrying amount VND	Provision amount VND	Carrying amount VND	Provision amount VND
Receivables from related parties (Note 42)	9,304,805,959	-	7,412,661,319	-
Receivables from third parties	641,632,216,348	(20,083,288,059)	607,769,960,716	(19,615,426,967)
	650,937,022,307	(20,083,288,059)	615,182,622,035	(19,615,426,967)

As at 30 June 2026 and 31 December 2025, there was no trade receivables from third parties accounting for 10% or more of total trade receivables.

9. SHORT-TERM ADVANCES TO SUPPLIERS

	Closing balance VND	Opening balance VND
Kanematsu KGK Vietnam Co., Ltd	10,958,557,059	-
Hau Giang Industrial Zone's Basic Development Company	3,251,045,444	3,251,045,444
PI Logistics Corporation	1,717,489,808	6,443,574,964
Other	31,722,901,842	10,472,215,474
	47,649,994,153	20,166,835,882

10. OTHER RECEIVABLES

	Closing balance		Opening balance (Reclassified)	
	Carrying amount VND	Provision amount VND	Carrying amount VND	Provision amount VND
a. Short-term				
Receivables from employees	13,390,267,005	(9,614,746,886)	12,515,447,130	(9,952,746,886)
Other receivables	3,121,173,502	-	5,456,162,674	-
	16,511,440,507	(9,614,746,886)	17,971,609,804	(9,952,746,886)
b. Long-term				
Deposits	5,866,574,169	-	5,608,830,169	-
	5,866,574,169	-	5,608,830,169	-

11. BAD DEBTS

	Closing balance		
	Cost VND	Provision VND	Recoverable amount VND
Total amount of receivables and advances past due or not past due but impaired	111,612,167,510	(30,246,274,945)	81,365,892,565
In which:			
Trade receivables	101,449,180,624	(20,083,288,059)	81,365,892,565
Others	10,162,986,886	(10,162,986,886)	-

	Opening balance (Reclassified)		
	Cost VND	Provision VND	Recoverable amount VND
Total amount of receivables and advances past due or not past due but impaired	84,051,050,169	(30,116,413,853)	53,934,636,316
<i>In which:</i>			
Trade receivables	73,550,063,283	(19,615,426,967)	53,934,636,316
Others	10,500,986,886	(10,500,986,886)	-

As at 30 June 2026 and 31 December 2025, there was no single receivable accounting for 10% or more of total amount of receivables past due or not past due but impaired.

Movements in the provision for doubtful debts, advances during the current period and prior year were as follows:

	Current period VND	Prior year (Reclassified) VND
Opening balance	30,116,413,853	33,047,572,645
Additional provision during the period/year	129,861,092	127,808,021
Write-off during the period/year	-	(2,922,934,609)
Reclassified to the provision for financial investments in accordance with Circular No. 99/2025/TT-BTC	-	(136,032,204)
Closing balance	30,246,274,945	30,116,413,853

12. INVENTORIES

	Closing balance		Opening balance	
	Cost VND	Provision VND	Cost VND	Provision VND
Goods in transit	109,379,183,293	-	137,856,931,738	-
Raw materials	613,434,031,063	(593,068,126)	430,750,180,987	(876,500,226)
Work in progress	114,438,570,852	-	93,780,418,889	-
Finished goods	361,806,288,296	(2,173,873,950)	328,000,683,692	(1,267,643,198)
Merchandise	49,330,350,739	(9,586,653,980)	40,677,561,026	(4,425,339,075)
Goods on consignment	160,834,037	-	122,268,359	-
	1,248,549,258,280	(12,353,596,056)	1,031,188,044,691	(6,569,482,499)

Movements in the provision for inventories during current period and prior year were as follows:

	Current period VND	Prior year VND
Opening balance	6,569,482,499	2,414,092,851
Increase	5,785,875,957	4,369,724,772
Utilization	(1,762,400)	(214,335,124)
Closing balance	12,353,596,056	6,569,482,499

The provision for devaluation of inventories was made for inventories whose costs were higher than net realizable value.

13. DEFERRED EXPENSES

	<u>Closing balance</u>	<u>Opening balance</u>
	VND	VND
a. Short-term		
Operating lease	10,973,973,856	2,991,005,512
Others	19,184,434,585	9,996,470,096
	<u>30,158,408,441</u>	<u>12,987,475,608</u>
b. Long-term		
Tools and supplies	5,949,585,685	5,088,841,814
Maintenance, replacement	19,943,217,331	25,634,776,170
Others	4,784,612,744	1,370,585,871
	<u>30,677,415,760</u>	<u>32,094,203,855</u>

DHG PHARMACEUTICAL JOINT STOCK COMPANY
NOTES TO THE INTERIM FINANCIAL STATEMENTS (Continued)

FORM B 09a-DN

14. INCREASES, DECREASES IN TANGIBLE FIXED ASSETS

	Buildings and structures	Machinery and equipment	Office equipment	Motor vehicles	Total
	VND	VND	VND	VND	VND
COST					
Opening balance	776,236,087,372	1,139,565,120,288	108,434,378,511	175,734,039,513	2,199,969,625,684
Purchases	262,599,186	5,942,560,084	3,081,569,087	106,654,374	9,393,382,731
Transfer from construction in progress	1,921,007,190	16,019,228,620	2,299,285,265	780,214,982	21,019,736,057
Reclassification	-	(30,930,000)	30,930,000	-	-
Closing balance	778,419,693,748	1,161,495,978,992	113,846,162,863	176,620,908,869	2,230,382,744,472
ACCUMULATED DEPRECIATION					
Opening balance	391,908,879,733	630,315,596,902	82,610,753,217	126,725,330,288	1,231,560,560,140
Charge for the period	12,613,698,821	37,581,264,891	3,222,618,959	4,587,153,286	58,004,735,957
Reclassification	-	(207,863)	207,863	-	-
Closing balance	404,522,578,554	667,896,653,930	85,833,580,039	131,312,483,574	1,289,565,296,097
NET BOOK VALUE					
Opening balance	384,327,207,639	509,249,523,386	25,823,625,294	49,008,709,225	968,409,065,544
Closing balance	373,897,115,194	493,599,325,062	28,012,582,824	45,308,425,295	940,817,448,375

As at 30 June 2026, the cost of the Company's fixed assets includes VND 704,267,541,984 (as at 31 December 2025: VND 681,700,314,561) of assets which have been fully depreciated but are still in use.

There are no tangible fixed assets currently in existence with a value equal to or greater than 10% of the total tangible fixed assets.

15. INCREASES, DECREASES IN INTANGIBLE FIXED ASSETS

	Land use rights with indefinite term VND	Land use rights with definite term VND	Computer software VND	Total VND
COST				
Opening and closing balance	83,120,604,201	129,637,853,493	21,530,169,027	234,288,626,721
ACCUMULATED AMORTIZATION				
Opening balance	-	38,658,033,180	21,210,724,625	59,868,757,805
Charge for the period	-	1,353,590,904	41,666,676	1,395,257,580
Closing balance	-	40,011,624,084	21,252,391,301	61,264,015,385
NET BOOK VALUE				
Opening balance	83,120,604,201	90,979,820,313	319,444,402	174,419,868,916
Closing balance	83,120,604,201	89,626,229,409	277,777,726	173,024,611,336

Details of existing intangible fixed assets are as follows:

	Cost VND	Net book value VND
Land use right of the DHG Pharmaceutical Plant at Lots B2-B3, Tan Phu Thanh Industrial Park – Phase 1, Thanh Xuan Commune, Can Tho City	56,022,387,810	41,863,357,345
Land use right at 288B Nguyen Van Cu Street, Cai Khe ward, Can Tho City	49,692,275,949	31,343,976,988
Others	128,573,962,962	99,817,277,003
	234,288,626,721	173,024,611,336

As at 30 June 2026, the cost of intangible fixed assets includes VND 21,106,017,479 (31 December 2025: VND 21,106,017,479) of assets which have been fully depreciated but are still in use.

16. INVESTMENT PROPERTIES

	Land use rights VND	Buildings and structures VND	Total VND
COST			
Opening balance and closing balance	36,063,405,215	8,763,205,928	44,826,611,143
ACCUMULATED DEPRECIATION			
Opening balance	6,872,425,424	8,089,945,976	14,962,371,400
Charge for the period	312,382,974	91,808,184	404,191,158
Closing balance	7,184,808,398	8,181,754,160	15,366,562,558
NET BOOK VALUE			
Opening balance	29,190,979,791	673,259,952	29,864,239,743
Closing balance	28,878,596,817	581,451,768	29,460,048,585

Details of existing investment properties are as follows:

	Cost	Net book value
	VND	VND
Land use rights and buildings at 170 - 172 Nguyen An Ninh Street, Ninh Kieu Ward, Can Tho City	12,299,867,069	9,299,724,346
Land use rights and buildings at 29 Ngo Quyen Street, Ninh Kieu Ward, Can Tho City	5,005,089,750	3,800,047,835
Land use rights and buildings at 44 Hai Ba Trung Street, Ninh Kieu Ward, Can Tho City	7,872,824,075	5,716,631,549
Land use rights and buildings at 89 Nguyen Van Troi Street, Hanoi	7,521,776,243	3,762,923,285
Land use rights and buildings at 68 Nguyen An Ninh Street, Ninh Kieu Ward, Can Tho City	6,617,568,136	4,872,639,115
Others	5,509,485,870	2,008,082,455
	44,826,611,143	29,460,048,585

As at 30 June 2026, the cost of investment properties included assets which were fully depreciated was VND 6,008,960,472 (as at 31 December 2025: VND 6,008,960,472).

Fair value of the Company's investment properties is VND 109,233,000,000, which was determined under latest valuation certificate issued on 5 August 2020 by South East Appraisal and Consulting Corporation and valuation certificate issued on 17 January 2023 by VAS Valuation Corporation Limited, both of which are independent valuation companies and are not related parties of the Company. South East Appraisal and Consulting Corporation and VAS Valuation Corporation Limited hold valid practicing certificates and had experience in real estate valuation. The valuations were conducted in accordance with Vietnamese Valuation Standards, with reference to market transaction prices of comparable properties.

17. CONSTRUCTION IN PROGRESS

	Closing balance		Opening balance	
	Cost	Recoverable amount	Cost	Recoverable amount
	VND	VND	VND	VND
Construction of Gia Lai branch office	3,473,948,774	3,473,948,774	3,473,948,774	3,473,948,774
Purchase of machinery and equipment	1,869,984,039	1,869,984,039	2,430,999,321	2,430,999,321
Renovation of the Representative office	-	-	6,489,712,485	6,489,712,485
Other renovation and repair works	25,331,533	25,331,533	-	-
Construction project of Finished goods warehouse no. 2	13,472,222,222	13,472,222,222	-	-
Expansion investment project for the DHG Pharmaceutical plant and Packaging Printing plant	31,435,080,720	31,435,080,720	31,762,966,020	31,762,966,020
	50,276,567,288	50,276,567,288	44,157,626,600	44,157,626,600

Movements in the construction in progress during the current period and prior year were as follows:

	Current period	Prior year
	VND	VND
Opening balance	44,157,626,600	48,613,976,834
Purchases	30,402,955,749	71,461,918,830
Transfer to tangible fixed assets (Note 14)	(21,019,736,057)	(60,908,772,914)
Transfer to deferred expenses and tools	(2,756,880,814)	(5,598,527,156)
Transfer to expenses during the period/year	(507,398,190)	(9,410,968,994)
	50,276,567,288	44,157,626,600

18. DEFERRED TAX ASSETS

	<u>Closing balance</u> VND	<u>Opening balance</u> VND
Corporate income tax rates used for determination of value of deferred tax assets	20%	20%
Deductible temporary differences		
<i>In which:</i>		
<i>Provision for dismantling and restoration costs</i>	16,735,976,773	16,292,235,516
<i>Provision for severance allowance</i>	5,771,285,726	5,734,587,367
<i>Provision for impairment of long-term financial investments</i>	3,951,675,811	3,895,675,812
<i>Unrealized gains arising from internal asset transactions</i>	3,144,139	6,917,106
Deferred tax assets	<u>26,462,082,449</u>	<u>25,929,415,801</u>

The deferred tax assets mainly arise from deductible temporary differences relating to provisions and unrealized profits arising from intra-group transactions of assets acquisition between the Company and its old subsidiaries in the Company which are dissolved.

Movement of deferred tax assets in the period/year was as follows:

	<u>Current period</u> VND	<u>Prior year</u> VND
Opening balance	25,929,415,801	18,339,519,916
Increase in deferred tax assets	536,439,615	7,597,441,819
Change of eliminated entry of fixed assets	(3,772,967)	(7,545,934)
Closing balance	<u>26,462,082,449</u>	<u>25,929,415,801</u>

19. SHORT-TERM TRADE PAYABLES

	<u>Closing balance</u> VND	<u>Opening balance</u> VND
a. Trade payables to third parties		
Nomura Trading Co., Ltd	27,786,785,200	71,709,171,625
Others	264,891,928,046	309,955,388,907
b) Trade payables to related parties (Note 42)	<u>29,747,855,451</u>	<u>9,966,094,632</u>
	<u>322,426,568,697</u>	<u>391,630,655,164</u>

As at 30 June 2026 and 31 December 2025, the Company did not have any short-term trade payables past due.

20. DIVIDENDS AND PROFIT PAYABLE

According to the General Meeting of Shareholders' Resolution No. 001/2026/NQ.ĐHĐCĐ dated 21 April 2026, the General Meeting of Shareholders approved a cash dividend distribution from the 2025 after-tax profits at a dividend rate of 100%, amounting to VND 1,307,460,710,000. On 28 May 2026, the Company made the first dividend payment at a rate of 50% of the par value of ordinary shares, amounting to VND 653,730,355,000. As at 30 June 2026, the outstanding dividend payable amounted to VND 653,730,355,000, which are expected to be paid in September 2026 in accordance with the aforementioned Resolution.

DHG PHARMACEUTICAL JOINT STOCK COMPANY
NOTES TO THE INTERIM FINANCIAL STATEMENTS (Continued)

FORM B 09a-DN

21. TAXES AND OTHER RECEIVABLES FROM/PAYABLES TO THE STATE BUDGET

	Opening balance	Payable	Paid	Waiting for net-off/ refund/other during the period	Closing balance
	VND	during the period	during the period	VND	VND
a. Tax receivables					
Personal income tax	-	(2,180,312,706)	-	16,008,154,525	13,827,841,819
Land rental and land use tax	707,643,716	(707,643,716)	-	-	-
Others	-	-	1,691,816,791	-	1,691,816,791
	707,643,716	(2,887,956,422)	1,691,816,791	16,008,154,525	15,519,658,610
b. Tax payables					
Value added tax for domestic goods	20,921,823,300	54,260,028,011	(54,797,509,511)	-	20,384,341,800
Value added tax for import goods	-	39,960,433,315	(39,960,433,315)	-	-
Import and export duties	-	3,060,161,460	(3,060,161,460)	-	-
Corporate income tax	5,272,441,091	68,302,019,842	(43,098,090,383)	-	30,476,370,550
Global minimum tax (*)	56,404,000,000	23,401,122,186	(23,179,917,219)	(13,204,967)	56,612,000,000
Personal income tax	5,632,148,715	27,154,855,186	(30,768,451,197)	-	2,018,552,704
Land rental and land use tax	-	12,465,088,393	(6,374,040,380)	-	6,091,048,013
Others	3,367,015,712	1,200,336,162	(4,505,286,386)	-	62,065,488
	91,597,428,818	229,804,044,555	(205,743,889,851)	(13,204,967)	115,644,378,555

(*) On 29 November 2023, the National Assembly issued Resolution No. 107/2023/QH15 relating to the application of top-up tax under the global anti-base erosion rules. As at the date of these financial statements, the Company's Management, based on the best estimate available at this time, has made an additional provision for corporate income tax obligations. Details of additional corporate income tax balance as at 30 June 2026 are as follows:

- As at 31 December 2025, the Company estimated the Global Minimum tax payable for the fiscal year 2025 was VND 33,012,000,000.
- As at 30 June 2026, the Company estimated the Global Minimum tax payable for the six-month financial period ended 30 June 2026 was VND 23,600,000,000.

22. PAYABLES TO EMPLOYEES

	Closing balance	Opening balance
	VND	VND
Salary expense	50,031,175,303	53,162,393,839
Bonus	141,099,056,345	186,797,860,031
Others	3,775,999,516	21,989,237,309
	194,906,231,164	261,949,491,179

23. SHORT-TERM ACCRUED EXPENSES

	Closing balance	Opening balance
	VND	VND
Land lease (*)	32,560,698,985	32,560,698,985
Payment discount	2,845,673,562	5,439,437,013
Recycling and packaging treatment costs (**)	935,040,902	4,000,000,000
Other accruals	36,040,351,011	28,921,470,572
	72,381,764,460	70,921,606,570

(*) The accrued land lease payable represents the Company's financial obligation related to the investment project for the expansion of the pharmaceutical manufacturing plant and the DHG packaging printing plant, which was handed over by the People's Committee of Hau Giang Province. This land lease obligation was estimated based on the applicable land lease rates and incentives, as stated in Land Lease Payment Notice No. 3571/TB-CTHAG dated 26 December 2022, issued by the Tax Department of Hau Giang Province. On 11 December 2024, the Company received Notice No. 631/TB-CTHAG from the Tax Department of Hau Giang Province regarding the cancellation of the aforementioned land lease payment notices. However, as a prudent measure, the Company continues to recognize this land lease expense until an official land fee notice is received from the relevant authority.

(**) Accruals for recycling and packaging treatment costs are made in accordance with the requirements of the Law on Environmental Protection 2020, Decree No. 05/2025/NĐ-CP dated 6 January 2025, and Decree No. 08/2022/NĐ-CP dated 10 January 2022 of the Government, which provide detailed guidance on the implementation of certain articles of the Law on Environmental Protection.

24. SHORT-TERM DEFERRED REVENUE

Short-term unearned revenue represents the unearned revenue for customer loyalty programs as presented in Note 4.

25. BONUS AND WELFARE FUNDS

The funds are established through appropriation from retained earnings upon approval of shareholders at the Company's Annual General Meetings ("AGM"). The funds are used to pay bonus and welfare to the Company's employees and cover operating expenses for the Board of Directors in accordance with the Company's bonus and welfare policies and the Company's AGM Resolution, respectively.



	Bonus and welfare fund	Operating fund of Board of Directors	Welfare fund in form of assets	Total
	VND	VND	VND	VND
Opening balance	1,611,477,141	10,059,943,891	7,231,884,445	18,903,305,477
Appropriation to the funds (Note 28)	25,570,623,227	-	-	25,570,623,227
Depreciation of assets formed from the funds	-	-	(94,969,866)	(94,969,866)
Utilization	(12,877,827,832)	(268,042,599)	-	(13,145,870,431)
Closing balance	14,304,272,536	9,791,901,292	7,136,914,579	31,233,088,407

26. PROVISIONS

	Provision for dismantling and restoration cost	Severance allowance	Total
	VND	VND	VND
Opening balance	81,461,177,581	28,672,936,835	110,134,114,416
Additional provision for the period	2,218,706,286	1,239,744,872	3,458,451,158
Utilization	-	(1,056,253,083)	(1,056,253,083)
Closing balance	83,679,883,867	28,856,428,624	112,536,312,491

In which:

Short-term

40,196,395,350

Long-term

72,339,917,141

27. SCIENCE AND TECHNOLOGY DEVELOPMENT FUNDS

In accordance with Circular No. 05/2022/TTLT-BKHCN-BTC dated 31 May 2022 issued by Ministry of Science and Technology and Circular No. 67/2022/TT-BTC dated 7 November 2022 issued by the Ministry of finance of Vietnam, enterprises are allowed to establish the science and technology development funds for research and development activities. Funds are utilized when disbursement are paid for research and development activities.

Movements of science and technology funds during the period were as follows:

	Scientific and technological development fund in form of assets
	VND
Opening balance	729,077,575
Depreciation of assets formed from the fund	(452,088,765)
Closing balance	276,988,810

DHG PHARMACEUTICAL JOINT STOCK COMPANY
NOTES TO THE INTERIM FINANCIAL STATEMENTS (Continued)

FORM B 09a-DN

28. OWNERS' EQUITY

Movement in owners' equity

	Owner's contributed capital	Share premium	Investment and development fund	Retained earnings	Total
	VND	VND	VND	VND	VND
Prior year's opening balance	1,307,460,710,000	6,778,948,000	2,458,122,657,972	322,392,781,997	4,094,755,097,969
Profit for the year	-	-	-	852,354,107,582	852,354,107,582
Dividends declared for 2024 – 2 nd time	-	-	-	(784,476,426,000)	(784,476,426,000)
Transfer to retained earnings	-	-	(1,100,000,000,000)	1,100,000,000,000	-
Appropriation to bonus and welfare fund	-	-	-	(23,367,603,599)	(23,367,603,599)
Appropriation to fund's operation for the Boards of Directors	-	-	-	(2,000,000,000)	(2,000,000,000)
Current period's closing balance	1,307,460,710,000	6,778,948,000	1,358,122,657,972	1,464,902,859,980	4,137,265,175,952
Profit for the period	-	-	-	614,344,840,477	614,344,840,477
Dividends declared for 2025	-	-	-	(1,307,460,710,000)	(1,307,460,710,000)
Appropriation to the bonus and welfare fund	-	-	-	(25,570,623,227)	(25,570,623,227)
Current period's closing balance	1,307,460,710,000	6,778,948,000	1,358,122,657,972	746,216,367,230	3,418,578,683,202

Charter capital

According to the amended Business Registration Certificate, the Company's charter capital is VND 1,307,460,710,000. The value and number of shares of the Company are as follows:

	Closing balance		Opening balance	
	Number of shares	VND	Number of shares	VND
Authorized and issued share capital	130,746,071	1,307,460,710,000	130,746,071	1,307,460,710,000
Ordinary shares currently in circulation	130,746,071	1,307,460,710,000	130,746,071	1,307,460,710,000

All ordinary shares have a par value of VND 10,000. Each share is entitled to one vote at shareholders' meetings. Shareholders are eligible to receive dividends declared by the Company. Ordinary shares are ranked equally with regard to the Company's residual assets.

Based on the shareholding structure as at 30 June 2026, the Company does not meet the criteria for being a public company as stipulated in Point a, Clause 1, Article 32 of the Law on Securities No. 54/2019/QH14, as amended and supplemented under Clause 11, Article 1 of Law No. 56/2024/QH15 dated 29 November 2024, due to not satisfying the minimum requirement that at least 10% of voting shares must be held by at least 100 investors who are not major shareholders. Accordingly, the Company may be required to carry out procedures for cancelling its public company status as prescribed. As at the date of issuance of these interim financial statements, the Company is still in discussion with its two major shareholders, Taisho and SCIC, to determine appropriate plans and solutions.

Dividends

According to the Resolution of the Company's Annual General Meeting No. 001/2026/NQ.ĐHĐCĐ dated 21 April 2026, the shareholders of the Company approved a cash dividend distribution from the 2025 after-tax profits at a dividend rate of 100%, equivalent to VND 1,307,460,710,000. Details are disclosed in Note 20.

Fund distribution

According to Resolution of the Company's Annual General Meeting No. 001/2026/NQ.ĐHĐCĐ dated 21 April 2026, the shareholders of the Company have approved the appropriation to the bonus and welfare fund of employees from profit after tax of 2025 at the rate of 3%, equivalent to the amount of VND 25,570,623,227.

29. OFF STATEMENT OF FINANCIAL POSITION ITEMS

Foreign currencies

Cash and cash equivalents included the following currencies:

	<u>Closing balance</u>	<u>Opening balance</u>
United States Dollar ("USD")	1,299,611	883,178
Euro ("EUR")	4,682	2,851
Yen ("JPY")	<u>275,944</u>	<u>276,670</u>

Bad debt written off

	<u>Closing balance</u>	<u>Opening balance</u>
	<u>VND</u>	<u>VND</u>
Bad debts written off	<u>17,300,208,475</u>	<u>17,429,208,475</u>

30. SEGMENTAL REPORTING

The primary format, product segments, is based on the Company's management and internal reporting structure.

Segment results include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items comprise assets and liabilities, financial income and expenses, selling expenses, general and administration expenses, other income or other expenses, and corporate income tax.

00-0
NHAI
TY T
A TO
OIT
T NA
HỒ

Product segments

In presenting information on the basis of product segments, segment revenue is disclosed for pharmaceutical products, nutritional supplements and others.

	<u>Current period</u>	<u>Prior period</u>
	<u>VND</u>	<u>VND</u>
Net sales		
Pharmaceutical products	2,115,243,594,967	1,998,195,056,755
Health-protecting supplements	237,313,141,173	186,552,794,065
Others	208,693,918,373	194,033,940,181
	<u>2,561,250,654,513</u>	<u>2,378,781,791,001</u>
Cost of sales		
Pharmaceutical products	(959,282,641,551)	(947,296,324,325)
Health-protecting supplements	(127,573,376,117)	(108,954,725,731)
Others	(166,367,258,875)	(169,918,253,559)
	<u>(1,253,223,276,543)</u>	<u>(1,226,169,303,615)</u>
Gross profit		
Pharmaceutical products	1,155,960,953,416	1,050,898,732,430
Health-protecting supplements	109,739,765,056	77,598,068,334
Others	42,326,659,498	24,115,686,622
	<u>1,308,027,377,970</u>	<u>1,152,612,487,386</u>

Geographical segments

Geographically, the Company primarily operates within the territory of Vietnam, with production activities and customer base mainly located in Vietnam, therefore there are no significant differences in risks and economic benefits by geographic segment that require disclosure in the interim financial statements.

31. NET REVENUE OF GOODS SOLD AND SERVICES RENDERED

	<u>Current period</u>	<u>Prior period</u>
	<u>VND</u>	<u>VND</u>
Sales of merchandise and services		
Sales of finished goods	2,665,577,134,819	2,571,351,559,326
Sales of merchandise	212,760,299,020	192,545,293,697
Others	2,095,338,942	2,131,936,255
	<u>2,880,432,772,781</u>	<u>2,766,028,789,278</u>
Deductions		
Sales discount	313,681,886,719	386,407,125,705
Sales return	5,500,231,549	839,872,572
	<u>319,182,118,268</u>	<u>387,246,998,277</u>
Net revenue		
<i>In which:</i>		
Sales of finished goods	2,354,053,696,340	2,186,207,898,020
Sales of merchandise	205,101,619,231	190,441,956,726
Others	2,095,338,942	2,131,936,255
	<u>2,561,250,654,513</u>	<u>2,378,781,791,001</u>

32. COST OF GOODS SOLD AND SERVICES RENDERED

	Current period	Prior period
	VND	VND
Cost of finished goods sold	1,082,084,230,914	1,057,257,779,557
Cost of merchandises sold	165,353,169,672	168,880,704,268
Additional provision for devaluation of inventories	5,785,875,957	30,819,790
	1,253,223,276,543	1,226,169,303,615

33. PRODUCTION AND OPERATING COSTS BY NATURE

	Current period	Prior period (Restated)
	VND	VND
Raw materials and consumables	1,029,002,572,929	1,019,825,089,787
Staff cost	554,767,198,975	519,979,917,865
Depreciation and amortization	59,246,037,201	59,006,711,415
Out-sourced services	162,376,671,040	161,467,539,033
Other expenses	138,321,470,836	135,094,363,328
Changes in inventory balances	(54,463,756,567)	(48,959,650,926)
Other transfers	(2,709,647,239)	(6,879,746,155)
	1,886,540,547,175	1,839,534,224,347

34. FINANCIAL INCOME

	Current period	Prior period
	VND	VND
Interest income	54,465,481,169	63,557,708,565
Foreign exchange gain	5,256,973,233	4,604,024,754
	59,722,454,402	68,161,733,319

35. FINANCIAL EXPENSES

	Current period	Prior period
	VND	VND
Settlement discount	17,854,966,269	21,779,136,012
Interest expense	-	12,697,085,263
Foreign exchange loss	4,637,101,647	8,362,886,275
Provision for/(reversal of) impairment of investments	280,000,000	(192,500,000)
Reversal of impairment provision for loans	(11,640,000)	-
Other financial expenses	54,359,682	54,359,682
	22,814,787,598	42,700,967,232

36. SELLING, GENERAL AND ADMINISTRATION EXPENSES

	Current period	Prior period
	VND	VND
Selling expenses		
- Staff cost	256,397,286,731	253,315,677,460
- Advertising expenses	21,021,510,195	48,775,282,719
- Others	176,029,764,398	154,559,574,588
	453,448,561,324	456,650,534,767
General and administration expenses		
- Staff cost	111,737,162,957	94,559,351,379
- Others	68,131,546,351	62,155,034,586
	179,868,709,308	156,714,385,965

37. OTHER INCOME

	Current period VND	Prior period VND
Compensation received	-	7,915,963,240
Income from the disposal of fixed assets	-	156,174,545
Gain from research services	83,998,264	-
Income from support received from Taisho	404,884,895	54,778,750
Others	1,019,321,149	1,299,143,514
	1,508,204,308	9,426,060,049

38. OTHER EXPENSES

	Current period VND	Prior period VND
Depreciation expense	338,974,163	399,666,258
Carrying amount of fixed assets and sale, disposal of fixed assets	89,300,000	-
Support expenses for individual business households	18,387,655	7,060,752,360
Tax reassessments and penalties	5,760,140,669	-
Others	1,403,860,106	1,134,206,689
	7,610,662,593	8,594,625,307

39. CURRENT CORPORATE INCOME TAX EXPENSE

	Current period VND	Prior period VND
Current corporate income tax expense		
Corporate income tax expense based on taxable profit in the current period in accordance with the Corporate Income Tax Law	64,466,160,245	52,738,004,730
Top-up tax expense under the Global Minimum Tax regulations	23,600,000,000	10,000,000,000
Adjustments for top-up tax expense under the Global Minimum Tax expense in previous years to the current corporate income tax expense in the current period	(198,877,814)	-
Adjustments for corporate income tax expense in previous years to the corporate income tax expense in the current period	3,835,859,597	-
Total current corporate income tax expense	91,703,142,028	62,738,004,730
	Current period VND	Prior period VND
Profit before tax	705,515,315,857	565,539,767,483
Tax rate	20%	20%
Tax calculated at a normal rate of 20%	141,103,063,171	113,107,953,497
Adjustments for		
Add back: non-deductible expenses	3,502,401,584	6,106,621,895
Temporary difference	836,853,349	403,893,293
Tax incentive	(80,976,157,859)	(66,880,463,955)
Corporate income tax expense based on taxable profit in the current period in accordance with the Corporate Income Tax Law	64,466,160,245	52,738,004,730

Applicable tax rate

From 1 April 2018, DHG Pharmaceutical One Member Limited Company ("DHG Pharmaceutical") and DHG Packaging and Printing 1 One Member Limited Company ("DHG Packaging and Printing 1") were merged into the Company and still entitled to tax incentives as follows:

- Pursuant to the Investment Certificate, DHG Packaging and Printing 1 is obliged to pay corporate income tax at the rate of 10% of taxable income from 2014 to 2028. Under terms in Investment Certificate granted to DHG Packaging and Printing 1, DHG Packaging and Printing 1 is entitled to corporate income tax exemption from 2014 to 2017 and 50% reduction of corporate income tax from 2018 to 2026.
- Pursuant to Investment Certificate No. 642041000005 issued by the Management Board of Hau Giang Industrial Zone, DHG Pharmaceutical is entitled to corporate income tax at the rate of 10% of taxable income for 15 years from 2015. DHG Pharmaceutical is entitled to the corporate income tax exemption for 4 years from 2015 and 50% reduction for the following 9 years commencing from 2019.

Pursuant to Official Letter No. 5610/TCT-CS dated 6 December 2017 issued by General Tax Authority, the aforementioned tax incentives are still applicable to the Company after its merger.

All above tax incentives are not applicable to remaining income which is entitled to the normal rate of 20%.

Changes in deferred tax income in the current and prior period are as follows:

	<u>Current period</u>	<u>Prior period</u>
	VND	VND
Deferred corporate tax income	(536,439,615)	(336,724,193)
Change of eliminated entries of fixed assets	3,772,967	3,772,967
	<u>(532,666,648)</u>	<u>(332,951,226)</u>

))

40. BASIC EARNINGS PER SHARE

a. Basic earnings per share

Basic earnings per share is calculated by dividing the net profit attributable to shareholders after deducting the bonus and welfare funds by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares repurchased by the Company and held as treasury shares.

	<u>Current period</u>	<u>Prior period</u>
	VND	(Restated) VND
Accounting profit after corporate income tax	614,344,840,477	503,134,713,979
Appropriation to funds (*)	(18,430,345,214)	(15,094,041,419)
Profit attributable to ordinary shareholders	595,914,495,263	488,040,672,560
Weighted average ordinary shares in circulation for the period (share)	130,746,071	130,746,071
Basic earnings per share (VND/share)	<u>4,558</u>	<u>3,733</u>

(*) Estimated amount appropriated to bonus and welfare funds for the 6-month period ended 30 June 2026 is determined based on the planned appropriation percentage of profit distribution to bonus and welfare funds at the rate of 3% in accordance with Resolution of the Company's Annual General Meeting No. 001/2026/NQ.DHDCĐ dated 21 April 2026.

For the purpose of presenting comparative figures for the financial statements for the 6-month period ended 30 June 2026, the Company has restated basic earnings per share for the 6-month period ended 30 June 2025 based on the actual bonus and welfare fund and the Board of Directors' operation fund distributed from profit of year 2025.

Details of the restatement of basic earnings per share are as follows:

	Previously reported amount	Changes	Restated amount
	VND	VND	VND
Profit after tax	503,134,713,979	-	503,134,713,979
Appropriation to fund (**)	(16,094,041,419)	1,000,000,000	(15,094,041,419)
Profit used to calculate earnings per share	487,040,672,560	1,000,000,000	488,040,672,560
Weighted average number of ordinary shares for the purpose of calculating basic earnings per share (shares)	130,746,071	130,746,071	130,746,071
Basic earnings per share (VND/share)	3,725	8	3,733

(**) The appropriation to the bonus and welfare fund and the Board of Directors' operation fund for the 6-month period ended 30 June 2025 has been restated based on the amounts approved under the Company's Annual General Meeting Resolution No. 001/2026/NQ.DHDCD dated 21 April 2026.

b. Diluted earnings per share

The Company does not have potentially diluted ordinary shares.

41. COMMITMENTS

a. Operating lease commitment

At the interim statement of financial position date, the Company had outstanding commitments under non-cancellable operating leases, which fall due as follows:

	Closing balance	Opening balance
	VND	VND
Within one year	31,310,261,167	25,496,958,563
In the second to fifth year inclusive	94,876,435,309	80,757,784,831
After five years	160,914,408,695	91,852,037,896
	287,101,105,171	198,106,781,290

b. Commitment related to major capital expenditure

Capital expenditure commitments for the acquisition and construction of property, plant and equipment at the interim statement of financial position date are as follows:

	Closing balance	Opening balance
	VND	VND
Approved but not contracted	43,825,252,367	41,163,401,129
Approved and contracted but not implemented	34,722,996,812	1,866,781,144
	78,548,249,179	43,030,182,273

According to Investment Registration Certificate No. 3753423003, as 11th amendment dated 27 February 2026, the Company obtained approval to increase the registered investment capital for the "Pharmaceutical Plant" project from VND 725 billion to VND 1,175 billion, and to adjust the scale and implementation schedule of the "Pharmaceutical Factory" project and the "Expansion of the Pharmaceutical Factory and DHG Printing and Packaging" project.

Details of the implementation progress of the committed projects are as follows:

Project	Expected operation date under the IRC	Implementation progress
Phase 4 – Project “Pharmaceutical Factory”		
- Finished Goods Warehouse No. 2	8/2027	Construction is currently underway with a total investment of VND 51,924,718,588 (including VAT). It is expected to be completed in September 2026.
- Utility system	3/2029	Not yet commenced.
- Non betalactam Manufacturing Facility	12/2029	Not yet commenced.
- NEW QC & RD Area	9/2030	Not yet commenced.
Phase 2 – Project “Expansion of DHG Pharmaceutical Factory and DHG Printing and Packaging”	2026	The Board of Directors approved the investment plan with the amount of VND 440 billion according to decision No. 020/2020/QĐ.HDQT dated 14 July 2020 and it is expected to be implemented after the completion of Phase 1. However, the Company is still working with the relevant government authorities to resolve outstanding issues and complete the necessary procedures required to proceed with the project. Accordingly, the Management intends to carry out the necessary procedures to apply for an extension of the project implementation period to ensure sufficient time to resolve the remaining matters before continuing the investment and construction activities.

42. RELATED PARTY TRANSACTIONS AND BALANCES

List of related parties:

Related party	Relationship
Taisho Pharmaceutical Co., Ltd ("Taisho")	Parent company
The State Capital Investment Corporation ("SCIC")	Significant influence shareholder
Hoe Pharmaceuticals Sdn Bhd	Taisho's related party
Taisho Pharmaceutical (Thailand) Co., Ltd	Taisho's related party
Taisho Pharmaceutical (Philippines), Inc	Taisho's related party
Taisho Pharmaceutical (Taiwan) Co., Ltd	Taisho's related party
Taisho Viet Nam Co., Ltd	Taisho's related party
Domesco Medical Import-Export Joint Stock Corporation	SCIC's related party

During the period, the Company entered into the following significant transactions with related parties:

	<u>Current period</u>	<u>Prior period</u>
	<u>VND</u>	<u>VND</u>
Sales of goods		
Taisho Pharmaceutical (Philippines), Inc	9,811,146,709	2,297,174,958
Domesco Medical Import-Export Joint Stock Corporation	4,726,188,000	-
Taisho Pharmaceutical (Thailand) Co., Ltd	434,729,916	1,034,412,005
	14,972,064,625	3,331,586,963
Purchases		
Taisho Pharmaceutical Co., Ltd	46,159,041,066	20,012,887,708
Taisho Viet Nam Co., Ltd	-	1,631,790,000
Taisho Pharmaceutical (Thailand) Co., Ltd	-	19,976,299
	46,159,041,066	21,664,654,007
Support received		
Taisho Pharmaceutical Co., Ltd	404,884,895	54,778,750
Free gifts/Promotion		
Taisho Pharmaceutical (Philippines), Inc	3,148,450	19,921,672
Taisho Pharmaceutical (Thailand) Co., Ltd	4,693,632	430,803
Taisho Pharmaceutical (Taiwan) Co., Ltd	2,613,566	-
	10,455,648	20,352,475
Dividends paid		
SCIC	283,131,185,000	566,262,370,000
Taisho Pharmaceutical Co., Ltd	333,485,260,000	666,970,520,000
	616,616,445,000	1,233,232,890,000

Remuneration paid to the Company's the Board of Directors and the Management during the period was as follows:

Name	Title	<u>Current period</u>	<u>Prior period</u>
		<u>VND</u>	<u>VND</u>
Mr. Toshiyuki Ishii	Board of Directors Member (until 21 April 2026) cum Chief Executive Officer (until 01 January 2026)	-	2,783,091,431
Ms. Dang Thi Thu Ha	Board of Directors Chairwoman	450,000,000	450,000,000
Mr. Do Le Hung	Board of Directors Member	405,000,000	405,000,000
Mr. Jun Kuroda	Board of Directors Member	360,000,000	360,000,000
Mr. Truong Anh Hung	Board of Directors Member	360,000,000	360,000,000
Mr. Maki Kamijo	Board of Directors Member	315,000,000	315,000,000
Ms. Le Thi Thanh Hien	Board of Directors Member	315,000,000	78,076,923
Ms. Sawa Sawada	Board of Directors Member (appointed on 21 April 2026)	82,115,385	-
Mr. Toshifumi Kojima	Acting General Director	1,285,434,436	-
Ms. Nguyen Ngoc Diep	Deputy General Director	2,290,724,750	2,985,074,429
Mr. Tomoyuki Kawata	Deputy General Director	1,838,644,850	1,447,771,286
Mr. Osamu Fujimori	Deputy General Director	1,908,579,000	895,473,087
Mr. Nguyen Ngoc Chuong	Production Director	1,222,116,100	816,652,411
Mr. Ta Thanh Hung	Information Technology Director	1,270,422,822	-
		12,103,037,343	10,896,139,567

Related party balances at the interim statement of financial position date were as follows:

	<u>Closing balance</u>	<u>Opening balance</u>
	VND	VND
Short-term trade receivables		
Hoe Pharmaceuticals Sdn Bhd	-	306,291,315
Domesco Medical Import-Export Joint Stock Corporation	4,816,337,400	-
Taisho Pharmaceutical (Philippines), Inc	4,488,468,559	7,106,370,004
	<u>9,304,805,959</u>	<u>7,412,661,319</u>
Other short-term receivables		
Taisho Viet Nam Co., Ltd	-	1,404,000,000
Short-term trade payables		
Taisho Pharmaceutical Co., Ltd	<u>29,747,855,451</u>	<u>9,966,094,632</u>
Advances from customers		
Taisho Pharmaceutical Co., Ltd	<u>2,702,442,324</u>	<u>1,922,611,856</u>
Dividend payables		
SCIC	283,131,185,000	-
Taisho Pharmaceutical Co., Ltd	333,485,260,000	-
	<u>616,616,445,000</u>	<u>-</u>

43. SUPPLEMENTAL DISCLOSURES OF INTERIM CASH FLOW INFORMATION

a. Non-cash transactions affecting the interim cash flow statement

	<u>Current period</u>	<u>Prior period</u>
	VND	VND
Appropriation to reserves	25,570,623,227	25,367,603,599
Transfer from construction in progress to tangible fixed assets	21,019,736,057	42,910,568,050
Transfer from Investment and Development fund to retained earnings	-	1,100,000,000,000
Transfer from construction in progress to deferred expenses and tools and equipment	2,756,880,814	5,598,527,156
Accrued interest payables	-	504,429,950
Accrued interest income	32,918,136,980	44,511,241,097
	<u>82,265,377,078</u>	<u>1,218,892,369,852</u>

b. Proceeds from borrowings

	<u>Current period</u>	<u>Prior period</u>
	VND	VND
Proceeds from borrowings under normal contracts under 3 months	-	133,141,033,625
Proceeds from borrowings under normal contracts over 3 months	-	1,352,569,329,050
	<u>-</u>	<u>1,485,710,362,675</u>

c. Repayment of borrowings

	Current period	Prior period
	VND	VND
Repayment of borrowings under normal contracts under 3 months	-	133,141,033,625
Repayment of borrowings under normal contracts over 3 months	-	1,074,913,916,414
	-	1,208,054,950,039

d. Others

	Closing balance	Opening balance
	VND	VND
Advances for the acquisition of fixed assets and construction in progress	25,332,004,575	2,364,202,587
Payables for the acquisition of fixed assets and construction in progress	1,146,194,060	7,807,751,224

44. SUBSEQUENT EVENTS

There is no other matter or circumstance that has arisen since the interim reporting period ended 30 June 2026 that requires adjustment or disclosure in the interim financial statements of the Company.


Tran Ngoc Hien
 Preparer


Ho Bui Huan
 Chief Accountant


Toshifumi Kojima
 Acting General Director
 Legal representative
 Approved on 13 August 2026

